Select Publications
Journal articles
2024, 'Sociodemographic and Health Factors of the Alcohol Treatment-seeking Population in New South Wales, Australia', Journal of addiction medicine, 18, pp. 619 - 627, http://dx.doi.org/10.1097/ADM.0000000000001311
,2024, 'Implementation of time-limited parenteral hydromorphone in people with treatment-resistant injecting opioid use disorder: a protocol for a single-site, uncontrolled, open-label study to assess feasibility, safety and cost', BMJ Open, 14, http://dx.doi.org/10.1136/bmjopen-2023-082553
,2024, 'Trends in reported GHB-related presentations to Sydney emergency departments between 2012 and 2021', EMA - Emergency Medicine Australasia, 36, pp. 604 - 608, http://dx.doi.org/10.1111/1742-6723.14402
,2024, 'Participant experiences in a pilot study for methamphetamine withdrawal treatment: Implications for retention', International Journal of Drug Policy, 126, http://dx.doi.org/10.1016/j.drugpo.2024.104383
,2024, 'Measuring Objective and Subjective Sleep during Lisdexamfetamine Treatment of Acute Methamphetamine Withdrawal: A Feasibility Study', European Addiction Research, 30, pp. 121 - 125, http://dx.doi.org/10.1159/000536328
,2024, 'Prescription psychostimulants for the treatment of amphetamine-type stimulant use disorder: A systematic review and meta-analysis of randomized placebo-controlled trials', Addiction, 119, pp. 211 - 224, http://dx.doi.org/10.1111/add.16347
,2024, 'Effect of a Smartphone App (S-Check) on Actual and Intended Help-Seeking and Motivation to Change Methamphetamine Use Among Adult Consumers of Methamphetamine in Australia: Randomized Waitlist-Controlled Trial', JMIR mHealth and uHealth, 12, http://dx.doi.org/10.2196/55663
,2023, '“There’s a big tag on my head”: exploring barriers to treatment seeking with women who use methamphetamine in Sydney, Australia', BMC Health Services Research, 23, pp. 162, http://dx.doi.org/10.1186/s12913-023-09125-z
,2023, 'Bupropion for treatment of amphetamine-type stimulant use disorder: A systematic review and meta-analysis of placebo-controlled randomized clinical trials', Drug and Alcohol Dependence, 253, http://dx.doi.org/10.1016/j.drugalcdep.2023.111018
,2023, 'Understandings, attitudes, practices and responses to GHB overdose among GHB consumers', Harm Reduction Journal, 20, pp. 121, http://dx.doi.org/10.1186/s12954-023-00857-z
,2023, 'Methamphetamine and emerging drugs of concern: A training needs analysis of Australian alcohol and other drug helplines', Drug and Alcohol Review, 42, pp. 1744 - 1753, http://dx.doi.org/10.1111/dar.13719
,2023, 'Substance use, socio-demographic characteristics, and self-rated health of people seeking alcohol and other drug treatment in New South Wales: baseline findings from a cohort study', Medical Journal of Australia, 219, pp. 218 - 226, http://dx.doi.org/10.5694/mja2.52039
,2023, 'Health and social characteristics of clients reporting amphetamine type substance use at entry to public alcohol and other drug services in New South Wales, Australia, 2016–2019', Drug and Alcohol Review, 42, pp. 389 - 400, http://dx.doi.org/10.1111/dar.13588
,2023, 'Meaningful cognitive decline is uncommon in virally suppressed HIV, but sustained impairment, subtle decline and abnormal cognitive aging are not', eClinicalMedicine, 56, pp. 101792, http://dx.doi.org/10.1016/j.eclinm.2022.101792
,2023, 'Inpatient GHB withdrawal management in an inner-city hospital in Sydney, Australia: a retrospective medical record review', Psychopharmacology, 240, pp. 127 - 135, http://dx.doi.org/10.1007/s00213-022-06283-6
,2023, 'Phenobarbital to manage severe gamma-hydroxybutyrate withdrawal: A case series', Drug and Alcohol Review, 42, pp. 27 - 32, http://dx.doi.org/10.1111/dar.13556
,2022, 'Lisdexamfetamine for the treatment of acute methamphetamine withdrawal: A pilot feasibility and safety trial', Drug and Alcohol Dependence, 241, pp. 109692, http://dx.doi.org/10.1016/j.drugalcdep.2022.109692
,2022, 'Playing at the edges, navigating sexual boundaries, and narrating sexual distress; Practices and perspectives of sexuality and gender diverse people who use GHB', International Journal of Drug Policy, 108, pp. 103811, http://dx.doi.org/10.1016/j.drugpo.2022.103811
,2022, 'Trial protocol of an open label pilot study of lisdexamfetamine for the treatment of acute methamphetamine withdrawal', PLoS ONE, 17, pp. e0275371, http://dx.doi.org/10.1371/journal.pone.0275371
,2022, 'Barriers to help-seeking among music festival attendees in New South Wales, Australia', Drug and Alcohol Review, 41, pp. 1322 - 1330, http://dx.doi.org/10.1111/dar.13479
,2022, 'Controlling for pleasure and risk: The experiences of sexuality and gender diverse people who use GHB', International Journal of Drug Policy, 105, pp. 103747, http://dx.doi.org/10.1016/j.drugpo.2022.103747
,2022, 'Individual level peer interventions for gay and bisexual men who have sex with men between 2000 and 2020: A scoping review', PLoS ONE, 17, http://dx.doi.org/10.1371/journal.pone.0270649
,2022, 'A clinical research priority setting study for issues related to the use of methamphetamine and emerging drugs of concern in Australia', Drug and Alcohol Review, 41, pp. 309 - 319, http://dx.doi.org/10.1111/dar.13350
,2022, 'Correlates of higher-risk drug-related behaviours at music festivals in New South Wales, Australia', Drug and Alcohol Review, 41, pp. 320 - 329, http://dx.doi.org/10.1111/dar.13404
,2022, 'Pharmacological treatment for methamphetamine withdrawal: A systematic review and meta-analysis of randomised controlled trials', Drug and Alcohol Review, 42, http://dx.doi.org/10.1111/dar.13511
,2022, 'Wastewater analysis for psychoactive substances at music festivals across New South Wales, Australia in 2019–2020', Clinical Toxicology, 60, pp. 440 - 445, http://dx.doi.org/10.1080/15563650.2021.1979233
,2021, 'One-third of people who inject drugs are at risk of incomplete treatment for Staphylococcus aureus bacteraemia: a retrospective medical record review', International Journal of Infectious Diseases, 112, pp. 63 - 65, http://dx.doi.org/10.1016/j.ijid.2021.09.012
,2021, 'Impact of the removal of patient co-payments for antiretroviral therapy (ART) on out-of-pocket expenditure, adherence and virological failure among Australian adults living with HIV', HEALTH POLICY, 125, pp. 1131 - 1139, http://dx.doi.org/10.1016/j.healthpol.2021.07.002
,2021, 'Safety and tolerability of oral lisdexamfetamine in adults with methamphetamine dependence: A phase-2 dose-escalation study', BMJ Open, 11, pp. e044696, http://dx.doi.org/10.1136/bmjopen-2020-044696
,2020, 'Pharmacological treatment of methamphetamine/amphetamine dependence: a systematic review', CNS Drugs, 34, pp. 337 - 365, http://dx.doi.org/10.1007/s40263-020-00711-x
,2019, 'Socioeconomic and psychosocial factors are associated with poor treatment outcomes in Australian adults living with HIV: A case-control study', Sexual Health, 16, pp. 548 - 553, http://dx.doi.org/10.1071/SH18138
,2018, 'Concomitant medication polypharmacy, interactions and imperfect adherence are common in Australian adults on suppressive antiretroviral therapy', AIDS, 32, pp. 35 - 48, http://dx.doi.org/10.1097/QAD.0000000000001685
,2017, 'Socioeconomic factors explain suboptimal adherence to antiretroviral therapy among HIV-infected Australian adults with viral suppression', PLoS ONE, 12, pp. e0174613, http://dx.doi.org/10.1371/journal.pone.0174613
,2016, 'Maraviroc-intensified combined antiretroviral therapy improves cognition in virally suppressed HIV-associated neurocognitive disorder', AIDS, 30, pp. 591 - 600, http://dx.doi.org/10.1097/QAD.0000000000000951
,2014, 'Is the HIV dementia scale a reliable tool for assessing HIV-relatedneurocognitive decline?', Journal of AIDS and Clinical Research, 5, http://dx.doi.org/10.4172/2155-6113.1000269
,Conference Papers
2024, 'OBJECTIVE AND SUBJECTIVE SLEEP DURING LISDEXAMFETAMINE TREATMENT OF ACUTE METHAMPHETAMINE WITHDRAWAL: NEW MEASUREMENT PARADIGM', in Drug and Alcohol Dependence, Elsevier BV, pp. 110067 - 110067, http://dx.doi.org/10.1016/j.drugalcdep.2023.110067
,2022, 'A qualitative exploration of client and healthcare provider perspectives on why people who inject drugs with injecting-related infections discharge against medical advice', in DRUG AND ALCOHOL REVIEW, WILEY, pp. S43 - S44, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000862018700077&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2022, 'Clients entering New South Wales alcohol and other drug treatment services: Characteristics by principal drug of concern, July 2016-June 2019', in DRUG AND ALCOHOL REVIEW, WILEY, pp. S31 - S32, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000862018700056&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2017, 'Failure of antiretroviral therapy (ART) in Australian adults is mainly due to ART toxicity', in Antiviral Therapy, International Medical Press, Milan, Italy, presented at The 19th International Workshop on Co-morbidities and Adverse Drug Reaction in HIV, Milan, Italy, 23 October 2017 - 25 October 2017, http://dx.doi.org/10.26190/unsworks/27395
,2017, 'Polypharmacy of concomitant medications in HIV-infected Australian adults is common, and associated with adverse effects', in Antiviral Therapy, International Medical Press, Milan, Italy, presented at The 19th International Workshop on Co-morbidities and Adverse Drug Reaction in HIV, Milan, Italy, 23 October 2017 - 25 October 2017, http://dx.doi.org/10.26190/unsworks/27403
,2017, 'Socioeconomic and psychosocial factors are associated with suboptimal outcomes in HIV-infected adults: a case-control analysis', in Antiviral Therapy, International Medical Press, Milan, Italy, presented at The 19th International Workshop on Co-morbidities and Adverse Drug Reaction in HIV, Milan, Italy, 23 October 2017 - 25 October 2017, http://dx.doi.org/10.26190/unsworks/27399
,2016, 'Concomitant medication use in ART-experienced Australian adults: data from the PAART study', in Antiviral Therapy, International Medical Press, New York City, USA, presented at The 18th International Workshop on Co-morbidities and Adverse Drug Reactions in HIV, New York City, USA, 12 September 2016 - 13 September 2016
,2013, 'Moderate neurocognitive decline can be detected over a four-month period using the HIV-dementia scale', in JOURNAL OF NEUROVIROLOGY, SPRINGER, DC, Washington, pp. S51 - S51, presented at 12th International Symposium on NeuroVirology, DC, Washington, 29 October 2013 - 02 November 2013, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000325777200107&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,Conference Posters
2024, 'An open-label safety and feasibility pilot trial of ketamine-assisted psychotherapy for methamphetamine use disorder', Canberra, Australia, presented at Australasian Professional Society on Alcohol and other Drugs (APSAD) Scientific Conference 2024, Canberra, Australia, 30 October 2024 - 02 November 2024, http://dx.doi.org/10.1111/dar.13943
,2024, 'The GHB cultures, experiences and practices quantitative study', Canberra, Australia, presented at Australasian Professional Society on Alcohol and other Drugs (APSAD) Scientific Conference 2024, Canberra, Australia, 30 October 2024 - 02 November 2024, http://dx.doi.org/10.1111/dar.13943
,2023, 'GHB Cultures, practices, and experiences: A qualitative study exploring diverse cultures, practices and experiences of GHB use among cisgender or transgender people who identify as heterosexual and live in Australia', Melbourne, Australia, presented at Harm Reduction International, Melbourne, Australia, 16 April 2023 - 20 April 2023, https://hr23.hri.global/programme/
,2023, 'Help wanted: Recruiting and leading nurses in the setup of Australia’s first supervised injectable opioid treatment clinic', Melbourne, Australia, presented at Harm Reduction International, Melbourne, Australia, 16 April 2023 - 19 April 2023, https://hr23.hri.global/programme/
,2022, 'The Safety and Feasibility of Lisdexamfetamine for the Treatment of Acute Methamphetamine Withdrawal: Preliminary Results of an Open Label Pilot Study', Minneapolis, USA, presented at The College on Problems of Drug Dependence 84th Annual Scientific Meeting, Minneapolis, USA, 11 June 2022 - 15 June 2022, https://d2p55c5k0gw6a2.cloudfront.net/wp-content/uploads/2022/07/2022-CPDD-Abstract-Book.pdf
,2022, 'Clinically significant cognitive decline is uncommon in virally suppressed HIV. However, there was a signal for abnormal aging and complex impact of psychosocial and socio-economic factors on longitudinal cognitive performance', Virtual, presented at Conference on Retroviruses and Opportunistic Infections, Virtual, 14 February 2022 - 16 February 2022
,2021, 'A clinical research network approach to a trial of lisdexamfetamine for the treatment of acute methamphetamine withdrawal', Virtual, Vol. 40, pp. S132 - S133, presented at The APSAD Scientific Drug and Alcohol Conference, Virtual, 07 November 2021 - 10 November 2021, http://dx.doi.org/10.1111/dar.13384
,